Rosnilimab

DB18851InvestigationalProtein Based Therapies

Rosnilimab is under investigation in clinical trial NCT06041269 (A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Rheumatoid Arthritis (RENOIR)).

Mechanism: Pharmacologically active on Programmed cell death protein 1
Curator reviewed
Also known as: Immunoglobulin g1, anti-(human programmed cell death protein 1) (human-mus musculus monoclonal anb030 .gamma.1-chain), disulfide with human-mus musculus monoclonal anb030 .kappa.-chain, dimer
Code names: ANB-030

Resolves to

Compound

UNII93OKX5KD2LCAS2412764-40-8

Targets

Q15116PDCD1

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Rosnilimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account